Middleway Nutrition
Evidence-based GLP-1 and peptide science.
Clear clinical research, dosing context, safety tradeoffs, and practical guides organized into two focused archives.
Latest Articles
20 articles
How Many Units Is 2.4 mg of Semaglutide?
2.4 mg is the top Wegovy maintenance dose. On a U-100 syringe it is 96 units at 2.5 mg/mL, 48 units at 5 mg/mL, and 24 units at 10 mg/mL. The concentration of your vial changes the answer, so confirm it before drawing.
GLP-1Retatrutide and the Grey Market: How Sourcing, Purity, and Risk Actually Work in 2026
Retatrutide has no consumer prescription, so demand has spilled into a grey market of research-grade powder and resellers. Here is how sourcing, purity testing, legality, and real risk actually work, plus harm reduction and legitimate alternatives.
GLP-1Retatrutide and Fertility: Ovulation, Conception, and Pregnancy
There is no human evidence that retatrutide impairs ovulation, sperm, or the reproductive axis. The real concern is exposure during pregnancy, which is contraindicated. This article separates those two questions and walks through what the trials measured and what they did not.
GLP-1Retatrutide for Beginners: The Complete Step-by-Step Start Guide (2026)
A plain-English \"start here\" guide for complete beginners to retatrutide, covering supplies, mixing, injecting, titration, side effects, and what to expect, framed honestly as investigational education, not medical advice.
GLP-1Cheapest GLP-1 in 2026: The Lowest-Cost Way to Get Each Drug
The lowest-cost ways to get a GLP-1 in 2026, ranked from cheapest to most expensive access path, plus the cheapest option for each individual drug.
GLP-1GLP-1 Price Comparison 2026: Every Drug and Every Way to Pay
A side-by-side cost comparison of every GLP-1 in 2026 across all five ways to pay: retail cash, manufacturer self-pay, GoodRx, insurance plus a savings card, and Medicare.
GLP-1GLP-1 Without a Doctor: The Grey Market, China Peptides, and What Actually Works in 2026
There is no legal way to buy GLP-1 medication in the US without a prescription. 'Research peptides' from China are not a loophole — the FDA has been issuing warning letters and seizing shipments through 2026, and contamination, fake dosing, and bacterial growth are routinely documented in seized batches.
GLP-1GLP-1 in Canada 2026: Approvals, CAD Prices, Provincial Coverage, and Telehealth
What's approved, what it costs in CAD, what your province actually covers, the shortage status after 2024, and how Felix, Maple, and other Canadian telehealth options fit. Cross-border buying is illegal — here's what works instead.
GLP-1GLP-1 Pen: How Every Major Injector Works, Doses, Storage, and Troubleshooting
Every GLP-1 brand uses a different pen — some single-dose, some four-dose, some you prime, some you don't. The Zepbound KwikPen (FDA-approved January 2026) now holds a full month in one device.
GLP-1Oral Wegovy vs Injectable Wegovy: Pill Or Weekly Shot?
Oral Wegovy and injectable Wegovy both contain semaglutide, but they differ in dosing routine, absorption, convenience, and practical adherence.
GLP-1GLP-1 for Pre-Diabetes: Trial Data, Type 2 Prevention Rates, and the FDA Gap
GLP-1 medications dramatically reduce progression from prediabetes to type 2 diabetes — up to 94% over 3 years in SURMOUNT-1, 80–84% reverting to normoglycemia in STEP — but no GLP-1 is FDA approved specifically for prediabetes.
GLP-1Is GLP-1 Insulin? No — They Are Two Different Hormones (and Two Different Drug Classes)
GLP-1 is not insulin. Insulin is a 51-amino-acid hormone made in the pancreas whose only job is to lower blood glucose. GLP-1 is a 30-amino-acid gut hormone that triggers your own pancreas to release insulin — and does a half-dozen other things insulin does not. They are commonly confused because both are injected and both are used in type 2 diabetes.
GLP-1GLP-1 and Joint Pain: Why Most People Get Better, and Why a Minority Get Worse
The STEP-9 trial showed semaglutide cut knee osteoarthritis pain by ~42 points on a 100-point scale at 68 weeks. But a small subgroup develops new joint pain on GLP-1s — almost always from rapid muscle loss, dehydration, gout flares, or post-loss biomechanics. Both directions explained.
GLP-1Amylin Agonist Guide: The Next Obesity Drug Pathway To Watch
Amylin agonists are emerging as a major obesity-drug pathway because they may complement GLP-1 appetite and metabolic effects.
GLP-1Cagrilintide Guide: The Amylin Analogue Behind CagriSema
Cagrilintide is an investigational long-acting amylin analogue being studied for obesity and metabolic disease, including in combination with semaglutide.
GLP-1CagriSema Guide: Cagrilintide Plus Semaglutide
CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide and semaglutide for weight management.
GLP-1GLP-1 After 3 Months: The Checkpoint That Decides the Next Year
At the 3-month mark, real-world data shows ~5.9% mean weight loss on semaglutide and 7–10% on tirzepatide. That number determines insurance coverage, dose decisions, and whether to switch drugs.
GLP-1GLP-1 Qualifications: Who Actually Qualifies in 2026 (BMI, Conditions, Age)
FDA approval criteria and insurance prior authorization criteria are not the same thing — and insurance is usually stricter. Here is who qualifies for a GLP-1 in 2026, what counts as a qualifying weight-related condition, and what to do if you don't qualify yet.
GLP-1GLP-1 After Gastric Bypass: Weight Regain, Timing, and Dose Guide
Adding a GLP-1 after gastric bypass or sleeve produces 5–15% additional weight loss in patients who plateaued or regained. Most surgeons wait at least 12 months post-op and prefer injectable over oral semaglutide.
GLP-1GLP-1 Success Stories: 10 Real Composite Patient Outcomes (and What Set the High Responders Apart)
Roughly 25–32% of trial patients on high-dose GLP-1s lose more than 20% of body weight. Real-world results are lower. Here are 10 composite stories showing the full range — from 100+ lb losses to non-responders — and what separates them.